In a significant move toward advancing artificial intelligence in drug discovery, Peptris, an innovative startup, has successfully raised $1 million in its pre-seed funding round led by Speciale Invest.
Peptris, co-founded by Narayanan Venkatasubramanian, Anand Budni, and Amit Mahajan, stands at the forefront of AI-driven drug research and discovery. The recently acquired funds are earmarked to intensify the company’s efforts in pioneering AI solutions to address unmet medical needs, particularly in the challenging domains of rare diseases, inflammation, and oncology.
The core of Peptris’s groundbreaking approach lies in its AI/ML-based computational platform, designed to expedite the drug discovery process. By leveraging artificial intelligence, the startup significantly reduces the time traditionally required for lab testing. This is achieved by efficiently navigating massive datasets to identify and develop potential drug candidates swiftly.
The company’s focus on creating new treatments for previously unsolvable targets is a strategic response to the urgent demands of rare diseases, encompassing over 7,000 known conditions lacking approved treatments. Peptris aims to reshape the drug discovery landscape by employing cutting-edge technology to tackle challenges that have long hindered progress in these critical medical areas.
As Peptris continues to push the boundaries of innovation, the funding injection from Speciale Invest is poised to play a pivotal role in accelerating the development of AI-powered solutions that promise to transform the future of drug discovery. The startup’s commitment to making advancements in medical research, particularly for conditions with limited therapeutic options, positions Peptris as a key player in the evolving landscape of AI-driven pharmaceutical breakthroughs.
